Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic.
Journal
NPJ Regenerative medicine
ISSN: 2057-3995
Titre abrégé: NPJ Regen Med
Pays: United States
ID NLM: 101699846
Informations de publication
Date de publication:
01 Nov 2021
01 Nov 2021
Historique:
received:
13
05
2021
accepted:
07
10
2021
entrez:
2
11
2021
pubmed:
3
11
2021
medline:
3
11
2021
Statut:
epublish
Résumé
The translation of laboratory-scale bioprocess protocols and technologies to industrial scales and the application of human induced pluripotent stem cell (hiPSC) derivatives in clinical trials globally presents optimism for the future of stem-cell products to impact healthcare. However, while many promising therapeutic approaches are being tested in pre-clinical studies, hiPSC-derived products currently account for a small fraction of active clinical trials. The complexity and volatility of hiPSCs present several bioprocessing challenges, where the goal is to generate a sufficiently large, high-quality, homogeneous population for downstream differentiation-the derivatives of which must retain functional efficacy and meet regulatory safety criteria in application. It is argued herein that one of the major challenges currently faced in improving the robustness of routine stem-cell biomanufacturing is in utilizing continuous, meaningful assessments of molecular and cellular characteristics from process to application. This includes integrating process data with biological characteristic and functional assessment data to model the interplay between variables in the search for global optimization strategies. Coupling complete datasets with relevant computational methods will contribute significantly to model development and automation in achieving process robustness. This overarching approach is thus crucially important in realizing the potential of hiPSC biomanufacturing for transformation of regenerative medicine and the healthcare industry.
Identifiants
pubmed: 34725374
doi: 10.1038/s41536-021-00183-7
pii: 10.1038/s41536-021-00183-7
pmc: PMC8560749
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
72Informations de copyright
© 2021. The Author(s).
Références
Kirouac, D. C. & Zandstra, P. W. The systematic production of cells for cell therapies. Cell Stem Cell 3, 369–381 (2008).
pubmed: 18940729
doi: 10.1016/j.stem.2008.09.001
Jenkins, M. J. & Farid, S. S. Human pluripotent stem cell-derived products: advances towards robust, scalable and cost-effective manufacturing strategies. Biotechnol. J. 10, 83–95 (2014).
pubmed: 25524780
pmcid: 4674985
doi: 10.1002/biot.201400348
Adil, M. M. & Schaffer, D. V. Expansion of human pluripotent stem cells. Curr. Opin. Chem. Eng. 15, 24–35 (2017).
doi: 10.1016/j.coche.2016.11.002
Kempf, H., Andree, B. & Zweigerdt, R. Large-scale production of human pluripotent stem cell derived cardiomyocytes. Adv. Drug Deliv. Rev. 96, 18–30 (2016).
pubmed: 26658242
doi: 10.1016/j.addr.2015.11.016
Kropp, C., Massai, D. & Zweigerdt, R. Progress and challenges in large-scale expansion of human pluripotent stem cells. Process Biochem. 59, 244–254 (2017).
doi: 10.1016/j.procbio.2016.09.032
Pellegrini, G. et al. From discovery to approval of an advanced therapy medicinal product-containing stem cells, in the EU. Regen. Med. 11, 407–420 (2016).
pubmed: 27091398
pmcid: 5561870
doi: 10.2217/rme-2015-0051
Yin, X. et al. Stem cell organoid engineering. Cell Stem Cell 18, 25–38 (2016).
pubmed: 26748754
pmcid: 4728053
doi: 10.1016/j.stem.2015.12.005
Chen, K. G. et al. Pluripotent stem cell platforms for drug discovery. Trends Mol. Med. 24, 805–820 (2018).
pubmed: 30006147
pmcid: 6117164
doi: 10.1016/j.molmed.2018.06.009
Romito, A. & Cobellis, G. Pluripotent stem cells: current understanding and future directions. Stem Cells Int. 2016, 1–20 (2016).
doi: 10.1155/2016/9451492
Thomson, J. A. et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 1145–1147 (1998).
doi: 10.1126/science.282.5391.1145
pubmed: 9804556
Caulfield, T. et al. International stem cell environments: a world of difference. Nat. Rep. Stem Cells 1, 1–5 (2009).
Kim, K. et al. Epigenetic memory in induced pluripotent stem cells. Nature 467, 285–290 (2010).
pubmed: 20644535
pmcid: 3150836
doi: 10.1038/nature09342
Robinton, D. A. & Daley, G. Q. The promise of induced pluripotent stem cells in research and therapy. Nature 481, 295–305 (2012).
pubmed: 22258608
pmcid: 3652331
doi: 10.1038/nature10761
Flavahan, W. A., Gaskell, E. & Bernstein, B. E. Epigenetic plasticity and the hallmarks of cancer. Science 357, 1–9 (2017).
doi: 10.1126/science.aal2380
Volarevic, V. et al. Ethical and safety issues of stem cell-based therapy. Int. J. Med. Sci. 15, 36–45 (2018).
pubmed: 29333086
pmcid: 5765738
doi: 10.7150/ijms.21666
Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861–872 (2007).
doi: 10.1016/j.cell.2007.11.019
pubmed: 18035408
Bai, L. et al. Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models. Nat. Neurosci. 15, 862–870 (2012).
pubmed: 22610068
pmcid: 3427471
doi: 10.1038/nn.3109
Trounson, A. & McDonald, C. Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell 17, 11–22 (2015).
doi: 10.1016/j.stem.2015.06.007
pubmed: 26140604
Garbern, J. C. & Lee, R. T. Cardiac stem cell therapy and the promise of heart regeneration. Cell Stem Cell 12, 689–698 (2013).
pubmed: 23746978
pmcid: 3756309
doi: 10.1016/j.stem.2013.05.008
Trounson, A. & DeWitt, N. D. Pluripotent stem cells progressing to the clinic. Nat. Rev. Mol. Cell Biol. 17, 194–200 (2016).
pubmed: 26908143
doi: 10.1038/nrm.2016.10
Braganca, J., Lopes, J. A., Mendes-Silva, L. & Santos, J. M. A. Induced pluripotent stem cells, a giant leap for mankind therapeutic applications. World J. Stem Cells 11, 421–430 (2019).
pubmed: 31396369
pmcid: 6682501
doi: 10.4252/wjsc.v11.i7.421
Kim, M. & Kino-oka, M. Bioengineering considerations for a nurturing way to enhance scalable expansion of human pluripotent stem cells. Biotechnol. J. 15, 1–16 (2020).
Wu, S. M. & Hochedlinger, K. Harnessing the potential of induced pluripotent stem cells for regenerative medicine. Nat. Cell Biol. 13, 497–505 (2011).
pubmed: 21540845
pmcid: 3617981
doi: 10.1038/ncb0511-497
Lund, R. J., Narva, E. & Lahesmaa, R. Understanding the genetics behind complex human disease with large-scale iPSC collections. Nat. Rev. Genet. 13, 732–744 (2012).
pubmed: 22965355
doi: 10.1038/nrg3271
Popp, B. et al. Need for high-resolution Genetic Analysis in iPSC: results and lessons from the ForIPS consortium. Sci. Rep. 8, 1–14 (2018).
doi: 10.1038/s41598-018-35506-0
Liang, G. & Zhang, Y. Genetic and epigenetic variations in iPSCs: potential causes and implications for application. Cell Stem Cell 13, 149–159 (2013).
pubmed: 23910082
pmcid: 3760008
doi: 10.1016/j.stem.2013.07.001
Merkle, F. T. et al. Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations. Nature 545, 229–233 (2017).
pubmed: 28445466
pmcid: 5427175
doi: 10.1038/nature22312
Cao, J. et al. Cells derived from iPSC can be immunogenic—yes or no? Protein Cell 5, 1–3 (2014).
pubmed: 24474200
pmcid: 3938852
doi: 10.1007/s13238-013-0003-2
Liu, X., Li, W., Fu, X. & Xu, Y. The immunogenicity and immune tolerance of pluripotent stem cell derivatives. Front. Immunol. 8, 1–6 (2017).
doi: 10.3389/fimmu.2017.00645
Chhabra, A. Inherent immunogenicity or lack thereof of pluripotent stem cells: implications for cell replacement therapy. Front. Immunol. 8, 1–11 (2017).
doi: 10.3389/fimmu.2017.00993
Pera, M. F. Stem cells: the dark side of induced pluripotency. Nature 471, 46–47 (2011).
pubmed: 21368819
doi: 10.1038/471046a
Nishino, K. et al. DNA methylation dynamics in human induced pluripotent stem cells over time. PLoS Genet. 7, 1–14 (2011).
doi: 10.1371/journal.pgen.1002085
Youssef, A. A. et al. The promise and challenge of induced pluripotent stem cells for cardiovascular applications. JACC Basic Transl. Sci. 1, 510–523 (2016).
pubmed: 28580434
pmcid: 5451899
doi: 10.1016/j.jacbts.2016.06.010
D’Urso, A. & Brickner, J. H. Mechanisms of epigenetic memory. Trends Genet. 30, 230–236 (2014).
pubmed: 24780085
pmcid: 4072033
doi: 10.1016/j.tig.2014.04.004
Khoo, T. S. et al. Retention of somatic memory associated with cell identity, age and metabolism in induced pluripotent stem (iPS) cells reprogramming. Stem Cell Rev. Rep. 16, 251–261 (2020).
pubmed: 32016780
doi: 10.1007/s12015-020-09956-x
Lee, J. E. & Lee, D. R. Human embryonic stem cells: derivation, maintenance and cryopreservation. Int. J. Stem Cells 4, 1–8 (2011).
doi: 10.15283/ijsc.2011.4.1.9
Yamanaka, S. Induced pluripotent stem cells: past, present, and future. Cell Stem Cell 10, 678–684 (2012).
pubmed: 22704507
doi: 10.1016/j.stem.2012.05.005
Kyttala, A. et al. Genetic variability overrides the impact of parental cell type and determines iPSC differentiation potential. Stem Cell Rep. 6, 200–212 (2016).
doi: 10.1016/j.stemcr.2015.12.009
Kim, M. & Costello, J. DNA methylation: an epigenetic mark of cellular memory. Exp. Mol. Med. 49, 1–8 (2017).
doi: 10.1038/emm.2017.10
Nishizawa, M. et al. Epigenetic variation between human induced pluripotent stem cell lines is an indicator of differentiation capacity. Cell Stem Cell 19, 341–354 (2016).
pubmed: 27476965
doi: 10.1016/j.stem.2016.06.019
Schwartzentruber, J. et al. Molecular and functional variation in iPSC-derived sensory neurons. Nat. Genet. 50, 54–61 (2018).
pubmed: 29229984
doi: 10.1038/s41588-017-0005-8
Anguera, M. C. et al. Molecular signatures of human induced pluripotent stem cells highlight sex differences and cancer genes. Cell Stem Cell 11, 75–90 (2012).
pubmed: 22770242
pmcid: 3587778
doi: 10.1016/j.stem.2012.03.008
Ronen, D. & Benvenisty, N. Sex-dependent gene expression in human pluripotent stem cells. Cell Stem Cell 8, 923–932 (2014).
Rubin, J. B. et al. Sex differences in cancer mechanisms. Biol. Sex. Differences 11, 1–29 (2020).
doi: 10.1186/s13293-020-00291-x
Kass, S. U., Pruss, D. & Wolffe, A. P. How does DNA methylation repress transcription? Trends Genet. 13, 444–449 (1997).
pubmed: 9385841
doi: 10.1016/S0168-9525(97)01268-7
Perrera, V. & Martello, G. How does reprogramming to pluripotency affect genomic imprinting? Front. Cell Dev. Biol. 7, 1–16 (2019).
doi: 10.3389/fcell.2019.00076
Pick, M. et al. Clone‐ and gene‐specific aberrations of parental imprinting in human induced pluripotent stem cells. Stem Cells 27, 2686–2690 (2009).
pubmed: 19711451
doi: 10.1002/stem.205
Panoupoulos, A. D. et al. Aberrant DNA methylation in human iPSCs associates with MYC-binding motifs in a clone-specific manner independent of genetics. Cell Stem Cell 20, 505–517 (2017).
doi: 10.1016/j.stem.2017.03.010
Assou, S. et al. Recurrent genetic abnormalities in human pluripotent stem cells: definition and routine detection in culture supernatant by targeted droplet digital PCR. Stem Cell Rep. 14, 1–8 (2020).
doi: 10.1016/j.stemcr.2019.12.004
Lessard, J. A. & Crabtree, G. R. Chromatin regulatory mechanisms in pluripotency. Annu. Rev. Cell Dev. Biol. 26, 503–532 (2010).
pubmed: 20624054
pmcid: 3085914
doi: 10.1146/annurev-cellbio-051809-102012
Collier, A. J. & Rugg-Gunn, P. J. Identifying human naïve pluripotent stem cells−evaluating state‐specific reporter lines and cell‐surface markers. Bioessays 40, 1–12 (2018).
doi: 10.1002/bies.201700239
Efroni, S. et al. Global transcription in pluripotent embryonic stem cells. Cell Stem Cell 2, 437–447 (2008).
pubmed: 18462694
pmcid: 2435228
doi: 10.1016/j.stem.2008.03.021
Harvey, A. et al. Interplay between metabolites and the epigenome in regulating embryonic and adult stem cell potency and maintenance. Stem Cell Rep. 13, 573–589 (2019).
doi: 10.1016/j.stemcr.2019.09.003
Kapinas, K. et al. The abbreviated pluripotent cell cycle. J. Cell Physiol. 1, 9–20 (2013).
doi: 10.1002/jcp.24104
Mathieu, J. & Ruohola-Baker, H. Metabolic remodeling during the loss and acquisition of pluripotency. Development 144, 541–555 (2017).
pubmed: 28196802
pmcid: 5312031
doi: 10.1242/dev.128389
Hassani, S. et al. Inhibition of TGFβ signaling promotes ground state pluripotency. Stem Cell Rev. Rep. 10, 16–30 (2014).
pubmed: 24036899
doi: 10.1007/s12015-013-9473-0
Burgess, R. J., Agathocleous, M. & Morrison, S. J. Metabolic regulation of stem cell function. J. Intern. Med. 276, 12–24 (2014).
pubmed: 24697828
pmcid: 4119467
doi: 10.1111/joim.12247
Carey, B. W. et al. Reprogramming factor stoichiometry influences the epigenetic state and biological properties of induced pluripotent stem cells. Cell Stem Cell 6, 588–598 (2011).
doi: 10.1016/j.stem.2011.11.003
Baker, D. et al. Detecting genetic mosaicism in cultures of human pluripotent stem cells. Stem Cell Rep. 7, 998–1012 (2016).
doi: 10.1016/j.stemcr.2016.10.003
Wu, J., Yamauchi, T. & Belmonte, J. C. I. An overview of mammalian pluripotency. Development 143, 1644–1648 (2016).
pubmed: 27190034
doi: 10.1242/dev.132928
Pennings, S., Liu, K. J. & Qian, H. The stem cell niche: interactions between stem cells and their environment. Stem Cells Int. 2018, 1–3 (2018).
doi: 10.1155/2018/4879379
Efthymiou, A. G., Chen, G., Rao, M., Chen, G. & Boehm, M. Self-renewal and cell lineage differentiation strategies in human embryonic stem cells and induced pluripotent stem cells. Expert Opin. Biol. Ther. 14, 1333–1344 (2014).
pubmed: 24881868
pmcid: 6469346
doi: 10.1517/14712598.2014.922533
Liu, X. et al. Reprogramming roadmap reveals route to human induced trophoblast stem cells. Nature 586, 101–107 (2020).
pubmed: 32939092
doi: 10.1038/s41586-020-2734-6
Liu, M., Liu, N., Zang, R., Li, Y. & Yang, S. Engineering stem cell niches in bioreactors. World J. Stem Cells 5, 124–135 (2013).
pubmed: 24179601
pmcid: 3812517
doi: 10.4252/wjsc.v5.i4.124
Kilens, S. et al. Parallel derivation of isogenic human primed and naive induced pluripotent stem cells. Nat. Commun. 9, 1–13 (2018).
doi: 10.1038/s41467-017-02107-w
Saito, S. et al. Emerging roles of hypoxia-inducible factors and reactive oxygen species in cancer and pluripotent stem cells. Kaohsiung J. Med. Sci. 31, 279–286 (2015).
pubmed: 26043406
doi: 10.1016/j.kjms.2015.03.002
Borys, B. S. et al. Optimized serial expansion of human induced pluripotent stem cells using low‐density inoculation to generate clinically relevant quantities in vertical‐wheel bioreactors. Stem Cells Transl. Med. 9, 1036–1052 (2020).
pubmed: 32445290
pmcid: 7445025
doi: 10.1002/sctm.19-0406
Assou, S., Bouckenheimer, J. & De Vos, J. Concise Review: assessing the genome integrity of human induced pluripotent stem cells: what quality control metrics? Stem Cells Transl. Med. 36, 814–821 (2018).
doi: 10.1002/stem.2797
Buta, C. et al. Reconsidering pluripotency tests: do we still need teratoma assays? Stem Cell Res. 11, 552–562 (2013).
pubmed: 23611953
doi: 10.1016/j.scr.2013.03.001
Mao, A. S. & Mooney, D. J. Regenerative medicine: current therapies and future directions. Proc. Natl Acad. Sci. USA 112, 14452–14459 (2015).
pubmed: 26598661
pmcid: 4664309
doi: 10.1073/pnas.1508520112
Li, K., Zhang, M., Xie, F., Liu, P. & Xu, S. Differentiation of pluripotent stem cells for regenerative medicine. Biochem. Biophys. Res. Commun. 471, 1–4 (2016).
pubmed: 26851367
doi: 10.1016/j.bbrc.2016.01.182
Joddar, B. & Ito, Y. Artificial niche substrates for embryonic and induced pluripotent stem cell cultures. J. Biotechnol. 168, 218–228 (2013).
pubmed: 23707375
doi: 10.1016/j.jbiotec.2013.04.021
Baghbaderani, B. A. et al. Detailed characterization of human induced pluripotent stem cells manufactured for therapeutic applications. Stem Cell Rev. Rep. 12, 394–420 (2016).
pubmed: 27283945
doi: 10.1007/s12015-016-9662-8
Sart, S., Bejoy, J. & Li, Y. Characterization of 3D pluripotent stem cell aggregates and the impact of their properties on bioprocessing. Process Biochem. 59, 276–288 (2017).
doi: 10.1016/j.procbio.2016.05.024
Galvanauskas, V. et al. Current state and perspectives in modeling and control of human pluripotent stem cell expansion processes in stirred-tank bioreactors. Biotechnol. Prog. 33, 355–364 (2017).
pubmed: 28019701
doi: 10.1002/btpr.2431
Polanco, A., Kuang, B. & Yoon, S. Bioprocess technologies that preserve the quality of iPSCs. Trends Biotechnol. 38, 1128–1140 (2020).
pubmed: 32941792
doi: 10.1016/j.tibtech.2020.03.006
Tohyama, S. et al. Efficient large-scale 2D culture system for human induced pluripotent stem cells and differentiated cardiomyocytes. Stem Cell Rep. 9, 1406–1414 (2017).
doi: 10.1016/j.stemcr.2017.08.025
Lavon, N., Zimerman, M. & Itskovitz-Eldor, J. In Advances in Biochemical Engineering/Biotechnology Book Series, ABE 163, 22–37 (2017). Edited by Scheper, T., Zhong, J. Published by Springer-Verlag Berlin Heidelberg NewYork.
Oyetunde, T., Bao, F. S., Chen, J. W., Martin, H. C. & Tang, Y. J. Leveraging knowledge engineering and machine learning for microbial manufacturing. Biotechnol. Adv. 36, 1308–1315 (2018).
pubmed: 29729378
doi: 10.1016/j.biotechadv.2018.04.008
Zitnik, M. et al. Machine learning for integrating data in biology and medicine: principles, practice, and opportunities. Inf. Fusion 50, 71–91 (2019).
doi: 10.1016/j.inffus.2018.09.012
pubmed: 30467459
Doulgkeroglou, M. et al. Automation, monitoring, and standardization of cell product manufacturing. Front. Bioeng. Biotechnol. 8, 1–12 (2020).
doi: 10.3389/fbioe.2020.00811
Malta, T. M. et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell 173, 338–354 (2018).
pubmed: 29625051
pmcid: 5902191
doi: 10.1016/j.cell.2018.03.034
Sugimoto, K. Machine learning-driven label-free cell sorting for CAR-T cell manufacturing. Cytotherapy 21, S39 (2019).
doi: 10.1016/j.jcyt.2019.03.376
Williams, B. et al. Prediction of human induced pluripotent stem cell cardiac differentiation outcome by multifactorial process modeling. Front. Bioeng. Biotechnol. 8, 1–15 (2020).
doi: 10.3389/fbioe.2020.00851
Kobold, S. et al. A manually curated database on clinical studies involving cell products derived from human pluripotent stem cells. Stem Cell Rep. 15, 546–555 (2020).
doi: 10.1016/j.stemcr.2020.06.014
Deinsberger, J., Reisinger, D. & Weber, B. Global trends in clinical trials involving pluripotent stem cells: a systematic multi-database analysis. npj Regen. Med. 5, 1–13 (2020).
doi: 10.1038/s41536-020-00100-4
Sung, Y. et al. Long-term safety and tolerability of subretinal transplantation of embryonic stem cell-derived retinal pigment epithelium in Asian Stargardt disease patients. Br. J. Opthalmol. 105, 829–837 (2021).
doi: 10.1136/bjophthalmol-2020-316225
Mandai, M. et al. Autologous induced stem cell-derived retinal cells for macular degeneration. N. Engl. J. Med. 376, 1038–1046 (2017).
pubmed: 28296613
doi: 10.1056/NEJMoa1608368
Bloor, A. J. C. et al. Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study. Nat. Med. 26, 1720–1725 (2020).
pubmed: 32929265
doi: 10.1038/s41591-020-1050-x
Doss, M. X. & Sachinidis, A. Current challenges of iPSC-based modeling and therapeutic implications. Cells 8, 1–16 (2019).
doi: 10.3390/cells8050403
Dashtban, M., Panchalingam, K. M., Shafa, M. & Baghbaderani, B. A. Addressing manufacturing challenges for commercialization of iPSC-based therapies. Methods Mol. Biol. 2286, 179–198 (2021).
pubmed: 32430594
doi: 10.1007/7651_2020_288
Yamanaka, S. Pluripotent stem cell-based cell therapy – promise and challenges. Cell Stem Cell 27, 523–531 (2020).
pubmed: 33007237
doi: 10.1016/j.stem.2020.09.014
Ozay, E. I. et al. Cymerus iPSC-MSCs significantly prolong survival in a pre-clinical, humanized mouse model of Graft-vs-host disease. Stem Cell Res. 35, 1–13 (2019).
doi: 10.1016/j.scr.2019.101401
Menasche, P. et al. Transplantation of human embryonic stem cell-derived cardiovascular progenitors for severe ischemic left ventricular dysfunction. J. Am. Coll. Cardiol. 71, 429–438 (2018).
pubmed: 29389360
doi: 10.1016/j.jacc.2017.11.047
Kamao, H. et al. Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application. Stem Cell Rep. 2, 205–218 (2014).
doi: 10.1016/j.stemcr.2013.12.007
Wang, Y. et al. Human clinical-grade parthenogenetic ESC-derived dopaminergic neurons recover locomotive defects of nonhuman primate models of Parkinson’s disease. Stem Cell Rep. 11, 171–182 (2018).
doi: 10.1016/j.stemcr.2018.05.010